🧴
Dermatology
Therapies for skin conditions including atopic dermatitis, psoriasis, acne, and rare dermatological disorders.
Companies
0
Pipeline Drugs
427
Key People
599
Dermatology Pipeline (427 drugs)
Approved: 119Commercial: 52Approved/Commercial: 43Phase 2: 28Phase 3: 25Preclinical: 19Phase 1: 18Not Specified: 13Pre-clinical: 10Various: 5Phase 1/2: 5Phase 2b: 4Not specified: 4R&D: 3Preclinical/Phase 1: 3Development: 3Clinical Development: 3Not Applicable: 3Registrational: 2Proof of Concept: 2IND-Enabling: 2Research: 2Phase 1b: 2Filed: 2Discovery: 2Phase 2a: 2Platform: 2ANDA Filed/Approved: 2ANDA Filed/Development: 2Pre-IND: 2Phase 2/3: 2Various (Typically Phase 2-4): 2Pre-clinical / Early Clinical: 2Approved / Filed: 1Development/Registration: 1Pre-Clinical/Phase 1: 1Exploratory/Pre-clinical: 1OTC: 1Approved/Filed: 1Research/Pre-clinical: 1Development/Filing: 1Regulatory Review: 1In Development: 1Clinical Studies: 1BLA Filed: 1Oncology Program: 1Clinical Evaluation: 1Marketed: 1Manufacturing: 1Phase 3-ready: 1Pre-clinical to Commercial: 1Research to Commercial: 1Pre-clinical to Phase 3: 1Late-stage clinical: 1Approved/FDA-cleared: 1NDA/BLA Filed: 1Pre-clinical / Early Development: 1Pilot Study: 1Pre-clinical / Research: 1Marketed (EUA): 1Prescription Product: 1Phase 1b/2b (planned): 1N/A (Post-Approval Study): 1Preclinical / Phase 1: 1N/A (Supplement): 1Not Specified (Likely Phase 3/NDA): 1Clinical-Stage: 1Preclinical/Clinical-Stage: 1Screening/Diagnostic: 1Various (Typically Phase 3): 1
| Drug | Company | Indication | Phase |
|---|---|---|---|
| Ilumya (tildrakizumab) | Sun Pharmaceutical | Psoriasis | Approved |
| CEQUA (cyclosporine) | Sun Pharmaceutical | Dry Eye Disease | Approved |
| Absorica/Absorica LD | Sun Pharmaceutical | Severe Acne | Approved |
| Levulan Kerastick | Sun Pharmaceutical | Actinic Keratosis | Approved |
| Biosimilar Portfolio | Sun Pharmaceutical | Various Oncology/Autoimmune | Phase 3 |
| SCD-044 | Sun Pharmaceutical | Psoriasis | Phase 2 |
| Generic Pipeline | Sun Pharmaceutical | Multiple | Various |
| Epiduo/Epiduo Forte | Galderma Group | Acne Vulgaris | Approved |
| Differin | Galderma Group | Acne Treatment | Approved |
| MetroGel | Galderma Group | Rosacea | Approved |
| Restylane Portfolio | Galderma Group | Aesthetic Dermal Fillers | Approved |
| Sculptra | Galderma Group | Aesthetic Enhancement | Approved |
| Dysport | Galderma Group | Aesthetic Neurotoxin | Approved |
| VYVGART® (efgartigimod) | Argenx | Generalized Myasthenia Gravis | Approved |
| Efgartigimod | Argenx | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 3 |
| ARGX-117 | Argenx | Complement-mediated diseases | Phase 1/2 |
| ARGX-118 | Argenx | Autoimmune diseases | Phase 1 |
| ARGX-119 | Argenx | Cancer | Phase 1 |
| Zynyz® (retifanlimab) | Incyte | Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) | Approved |
| Tabrecta® (capmatinib) | Incyte | METex14 Skipping Advanced Non-Small Cell Lung Cancer | Approved |
| Opzelura™ (ruxolitinib) cream | Incyte | Vitiligo and other dermatological conditions | Approved |
| Brepocitinib | Roivant Sciences | Dermatomyositis | Registrational |
| IMVT-1402 | Roivant Sciences | Graves' Disease | Registrational |
| Batoclimab | Roivant Sciences | Thyroid Eye Disease | Proof of Concept |
| Mosliciguat | Roivant Sciences | Pulmonary Hypertension associated with Interstitial Lung Disease | Proof of Concept |
| VTAMA (tapinarof) | Roivant Sciences | Plaque Psoriasis | Commercial |
| Semglee (insulin glargine biosimilar) | Viatris | Diabetes | Approved |
| Mvasi (bevacizumab biosimilar) | Viatris | Oncology | Approved |
| Ogivri (trastuzumab biosimilar) | Viatris | Breast Cancer | Approved |
| EpiPen | Viatris | Anaphylaxis | Approved |
| Lipitor | Viatris | Cardiovascular Disease | Approved |
| Lyrica | Viatris | Neuropathic Pain | Approved |
| Norvasc | Viatris | Hypertension | Approved |
| Viagra | Viatris | Erectile Dysfunction | Approved |
| Lanreotide Injection | Cipla | Neuroendocrine Tumors | Commercial |
| Biosimilar Bevacizumab | Cipla | Various Cancers | Commercial |
| Biosimilar Trastuzumab | Cipla | Breast Cancer | Commercial |
| Albuterol HFA | Cipla | Asthma/COPD | Commercial |
| Generic Advair Equivalent | Cipla | Asthma/COPD | Phase 3 |
| Biosimilar Rituximab | Cipla | Lymphoma/Leukemia | Commercial |
| Glatiramer Acetate | Cipla | Multiple Sclerosis | Commercial |
| Manforce | Mankind Pharma | Erectile Dysfunction | Commercial |
| Asomex | Mankind Pharma | Hypertension | Commercial |
| Gas-O-Fast | Mankind Pharma | Antacid/Digestive Health | Commercial |
| Prega News | Mankind Pharma | Pregnancy Detection | Commercial |
| Unwanted-21 | Mankind Pharma | Oral Contraceptive | Commercial |
| AcneStar | Mankind Pharma | Acne Treatment | Commercial |
| Soframycin | Mankind Pharma | Topical Antibiotic | Commercial |
| ZyCoV-D | Zydus Lifesciences | COVID-19 | Approved |
| Saroglitazar | Zydus Lifesciences | Diabetic Dyslipidemia | Approved |
Key People in Dermatology
DS
Dilip Shanghvi
Managing Director and Founder
Sun Pharmaceutical
AS
Aalok Shanghvi
Executive Director
Sun Pharmaceutical
CM
C.S. Muralidharan
Chief Financial Officer
Sun Pharmaceutical
KG
Kirti Ganorkar
CEO - India Business
Sun Pharmaceutical
AG
Abhay Gandhi
CEO - North America
Sun Pharmaceutical
AP
Aditya Pinto
Executive Vice President - International Business
Sun Pharmaceutical
BM
Bill Meury
President and Chief Executive Officer
Incyte
PJ
Pablo J. Cagnoni, M.D.
President, Head of Research and Development
Incyte
SB
Soni Basi, Ph.D.
Executive Vice President and Chief Human Resources Officer
Incyte
MG
Matt Gline
Chief Executive Officer
Roivant Sciences
MG
Matt Gline
Director
Roivant Sciences
AG
Alex Gasner
Executive Vice President, Roivant Health
Roivant Sciences
DG
Daniel Gold
Director
Roivant Sciences
EV
Eric Valeur
Vice President, Head of Drug Discovery
Roivant Sciences
SA
Scott A. Smith
Chief Executive Officer
Viatris